Journal article
Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
Abstract
BACKGROUND: Standard of care for persons with severe hemophilia A includes regular replacement of factor VIII (FVIII). Prophylaxis regimens using standard half-life (SHL) FVIII concentrates, while effective, are costly and require frequent intravenous infusions.
AIM: This study evaluated the adherence of 56 boys with severe hemophilia A to tailored, frequency-escalated prophylaxis with an SHL recombinant FVIII concentrate.
Authors
Dover S; Blanchette VS; Wrathall D; Pullenayegum E; Kazandjian D; Song B; Hawes SA; Cloutier S; Rivard GE; Klaassen RJ
Journal
Research and Practice in Thrombosis and Haemostasis, Vol. 4, No. 2,
Publisher
Elsevier
Publication Date
February 2020
DOI
10.1002/rth2.12301
ISSN
2475-0379